TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT05636618: Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Sponsor: Perspective Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 300 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$6,950,790

Rescue Site Savings

+$4,594,590

Unlock Full NCT05636618 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05636618 Rescue Dossier →